<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37600795</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>22</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>31</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>IFN-&#x3b1; induced systemic lupus erythematosus complicated with hemophagocytic lymphohistiocytosis: a case report and literature review.</ArticleTitle><Pagination><StartPage>1223062</StartPage><MedlinePgn>1223062</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1223062</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2023.1223062</ELocationID><Abstract><AbstractText>Hemophagocytic lymphohistiocytosis (HLH) is a severe and life-threatening hyperinflammatory condition characterized by excessive activation of macrophages and T cells and resulted in multi-organ dysfunction. HLH can be a primary disease or secondary to infections, malignancy, and some autoimmune diseases, including adult-onset Still's disease (AOSD) and systemic lupus erythematosus (SLE). However, it is rare for HLH to occur as a secondary condition to drug-induced lupus erythematosus (DILE). In this report, we present a case of HLH as an unusual complication during SLE treatment in a 31-year-old male patient. The patient initially suffered from active chronic hepatitis B (CHB) and was treated with pegylated INF&#x3b1;-2b (Peg-INF&#x3b1;-2b), tenofovir disoproxil and lamivudine. After 19 months, CHB obtained biochemical and virological response with HBsAg positive to HBsAb. The patient developed fever, headache, and cytopenia after Peg-INF&#x3b1;-2b treatment for 33 months, and laboratory studies revealed that ANA and anti dsDNA were positive. He displayed 5 features meeting the HLH-2004 criteria for diagnosis including fever, pancytopenia, hyperferritinemia, high levels of soluble CD25, and hemophagocytosis on bone marrow biopsy. The patient was initiated with a combination treatment of intravenous methylprednisolone pulse therapy, oral cyclosporine, and etoposide (VP-16), which was followed by a course of oral prednisolone, intravenous cyclophosphamide pulse therapy, and entecavir with complete response. To our knowledge, this is the first report of IFN-&#x3b1; induced SLE complicating with HLH. Physicians should consider the potential autoimmune side effects of IFN-&#x3b1; therapy and be alert to insidious HLH in patients diagnosed with SLE.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Zeng, Tu, Ji, Liu, Huang, Nie and Yang.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zeng</LastName><ForeName>Zhipeng</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tu</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ji</LastName><ForeName>Bai</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, the People Hospital of Tongshan, Xianning, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Kecheng</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nie</LastName><ForeName>Daan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Cardiology, the Affiliated Hospital of Guizhou Medical University, Guiyang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Liu</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Reproductive Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051359" MajorTopicYN="Y">Lymphohistiocytosis, Hemophagocytic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001327" MajorTopicYN="Y">Autoimmune Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016898" MajorTopicYN="N">Interferon-alpha</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Hemophagocytic lymphohistiocytosis (HLH)</Keyword><Keyword MajorTopicYN="N">Peg-INF&#x3b1;-2b</Keyword><Keyword MajorTopicYN="N">hepatitis B virus (HBV)</Keyword><Keyword MajorTopicYN="N">interferon-&#x3b1;</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus (SLE)</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>22</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>21</Day><Hour>4</Hour><Minute>50</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37600795</ArticleId><ArticleId IdType="pmc">PMC10436618</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2023.1223062</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>De Benedetti F, Prencipe G, Bracaglia C, Marasco E, Grom AA. Targeting interferon-gamma in hyperinflammation: opportunities and challenges. Nat Rev Rheumatol (2021) 17(11):678&#x2013;91. doi: 10.1038/s41584-021-00694-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-021-00694-z</ArticleId><ArticleId IdType="pubmed">34611329</ArticleId></ArticleIdList></Reference><Reference><Citation>Gota C, Calabrese L. Induction of clinical autoimmune disease by therapeutic interferon-alpha. Autoimmunity (2003) 36(8):511&#x2013;8. doi: 10.1080/08916930310001605873</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08916930310001605873</ArticleId><ArticleId IdType="pubmed">14984028</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian J, Zhang D, Yao X, Huang Y, Lu Q. Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study. Ann Rheum Dis (2023) 82(3):351&#x2013;6. doi: 10.1136/ard-2022-223035</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard-2022-223035</ArticleId><ArticleId IdType="pmc">PMC9933169</ArticleId><ArticleId IdType="pubmed">36241363</ArticleId></ArticleIdList></Reference><Reference><Citation>Chasset F, Arnaud L. Targeting interferons and their pathways in systemic lupus erythematosus. Autoimmun Rev (2018) 17(1):44&#x2013;52. doi: 10.1016/j.autrev.2017.11.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2017.11.009</ArticleId><ArticleId IdType="pubmed">29108825</ArticleId></ArticleIdList></Reference><Reference><Citation>He Y, Sawalha AH. Drug-induced lupus erythematosus: an update on drugs and mechanisms. Curr Opin Rheumatol (2018) 30(5):490&#x2013;7. doi: 10.1097/BOR.0000000000000522</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOR.0000000000000522</ArticleId><ArticleId IdType="pmc">PMC7299070</ArticleId><ArticleId IdType="pubmed">29870500</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramos-Casals M, Brito-Zer&#xf3;n P, L&#xf3;pez-Guillermo A, Khamashta MA, Bosch X. Adult haemophagocytic syndrome. Lancet (2014) 383(9927):1503&#x2013;16. doi: 10.1016/S0140-6736(13)61048-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(13)61048-X</ArticleId><ArticleId IdType="pubmed">24290661</ArticleId></ArticleIdList></Reference><Reference><Citation>Henter J-I, Horne A, Aric&#xf3; M, Egeler RM, Filipovich AH, Imashuku S, et al. . HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer (2007) 48(2):124&#x2013;31. doi: 10.1002/pbc.21039</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pbc.21039</ArticleId><ArticleId IdType="pubmed">16937360</ArticleId></ArticleIdList></Reference><Reference><Citation>Fardet L, Galicier L, Lambotte O, Marzac C, Aumont C, Chahwan D, et al. . Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol (2014) 66(9):2613&#x2013;20. doi: 10.1002/art.38690</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.38690</ArticleId><ArticleId IdType="pubmed">24782338</ArticleId></ArticleIdList></Reference><Reference><Citation>Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. . European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis (2019) 2019) 78(9):1151&#x2013;9. doi: 10.1136/annrheumdis-2018-214819</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2018-214819</ArticleId><ArticleId IdType="pubmed">31383717</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang LSY, Covert E, Wilson E, Kottilil S. Chronic hepatitis B infection: A review. JAMA (2018) 319(17):1802&#x2013;13. doi: 10.1001/jama.2018.3795</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2018.3795</ArticleId><ArticleId IdType="pubmed">29715359</ArticleId></ArticleIdList></Reference><Reference><Citation>Yardeni D, Chang K-M, Ghany MG. Current best practice in hepatitis B management and understanding long-term prospects for cure. Gastroenterology (2023) 164(1):42&#x2013;60. doi: 10.1053/j.gastro.2022.10.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2022.10.008</ArticleId><ArticleId IdType="pmc">PMC9772068</ArticleId><ArticleId IdType="pubmed">36243037</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau GKK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. . Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. New Engl J Med (2005) 352(26):2682&#x2013;95. doi: 10.1056/NEJMoa043470</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa043470</ArticleId><ArticleId IdType="pubmed">15987917</ArticleId></ArticleIdList></Reference><Reference><Citation>Capobianchi MR, Uleri E, Caglioti C, Dolei A. Type I IFN family members: similarity, differences and interaction. Cytokine Growth Factor Rev (2015) 26(2):103&#x2013;11. doi: 10.1016/j.cytogfr.2014.10.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cytogfr.2014.10.011</ArticleId><ArticleId IdType="pmc">PMC7108279</ArticleId><ArticleId IdType="pubmed">25466633</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang C, Gershwin ME. Drug-induced lupus erythematosus: incidence, management and prevention. Drug Saf (2011) 34(5):357&#x2013;74. doi: 10.2165/11588500-000000000-00000</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/11588500-000000000-00000</ArticleId><ArticleId IdType="pubmed">21513360</ArticleId></ArticleIdList></Reference><Reference><Citation>Durcan L, O'Dwyer T, Petri M. Management strategies and future directions for systemic lupus erythematosus in adults. Lancet (2019) 393(10188):2332&#x2013;43. doi: 10.1016/S0140-6736(19)30237-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(19)30237-5</ArticleId><ArticleId IdType="pubmed">31180030</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonov D, Kazandjieva J, Etugov D, Gospodinov D, Tsankov N. Drug-induced lupus erythematosus. Clin Dermatol (2004) 22(2):157&#x2013;66. doi: 10.1016/j.clindermatol.2003.12.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clindermatol.2003.12.023</ArticleId><ArticleId IdType="pubmed">15234017</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed MM, Berney SM, Wolf RE, Hearth-Holmes M, Hayat S, Mubashir E, et al. . Prevalence of active hepatitis C virus infection in patients with systemic lupus erythematosus. Am J Med Sci (2006) 331(5):252&#x2013;6. doi: 10.1097/00000441-200605000-00003</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00000441-200605000-00003</ArticleId><ArticleId IdType="pubmed">16702794</ArticleId></ArticleIdList></Reference><Reference><Citation>Psarras A, Wittmann M, Vital EM. Emerging concepts of type I interferons in SLE pathogenesis and therapy. Nat Rev Rheumatol (2022) 18(10):575&#x2013;90. doi: 10.1038/s41584-022-00826-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-022-00826-z</ArticleId><ArticleId IdType="pubmed">36097207</ArticleId></ArticleIdList></Reference><Reference><Citation>Deeks ED. Anifrolumab: first approval. Drugs (2021) 81(15):1795&#x2013;802. doi: 10.1007/s40265-021-01604-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-021-01604-z</ArticleId><ArticleId IdType="pubmed">34554438</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizvi R, Hojjati M. Interferon-&#x3b1; induced lupus in a patient with chronic hepatitis C virus. J Clin Rheumatol (2011) 17(3):152&#x2013;3. doi: 10.1097/RHU.0b013e31821557e7</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/RHU.0b013e31821557e7</ArticleId><ArticleId IdType="pubmed">21441813</ArticleId></ArticleIdList></Reference><Reference><Citation>Yilmaz S, Cimen KA. Pegylated interferon alpha-2B induced lupus in a patient with chronic hepatitis B virus infection: case report. Clin Rheumatol (2009) 28(10):1241&#x2013;3. doi: 10.1007/s10067-009-1239-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-009-1239-3</ArticleId><ArticleId IdType="pubmed">19653058</ArticleId></ArticleIdList></Reference><Reference><Citation>Onishi S, Nagashima T, Kimura H, Matsuyama Y, Yoshio T, Minota S. Systemic lupus erythematosus and Sj&#xf6;gren's syndrome induced in a case by interferon-alpha used for the treatment of hepatitis C. LUPUS (2010) 19(6):753&#x2013;5. doi: 10.1177/0961203309353172</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203309353172</ArticleId><ArticleId IdType="pubmed">20064909</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalil Ur R, Khokhar N. Development of systemic lupus erythematosus following interferon-&amp;alpha; therapy for hepatitis C infection. J Coll Physicians Surg Pak (2016) 26(3):223&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">26975957</ArticleId></ArticleIdList></Reference><Reference><Citation>Au&#xf1;&#xf3;n-Rubio P, Hern&#xe1;ndez-Mart&#xed;nez E, Sevillano-Prieto A, Morales-Ruiz E. Hepatitis C virus infection, interferon &#x3b1; and lupus; a curious combination. Nefrologia (2014) 34(4):534&#x2013;6. doi:&#xa0;10.3265/Nefrologia.pre2014.Apr.12349</Citation><ArticleIdList><ArticleId IdType="doi">10.3265/Nefrologia.pre2014.Apr.12349</ArticleId><ArticleId IdType="pubmed">25036072</ArticleId></ArticleIdList></Reference><Reference><Citation>Niewold TB, Swedler WI. Systemic lupus erythematosus arising during interferon-alpha therapy for cryoglobulinemic vasculitis associated with hepatitis C. Clin Rheumatol (2005) 24(2):178&#x2013;81. doi: 10.1007/s10067-004-1024-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-004-1024-2</ArticleId><ArticleId IdType="pubmed">15565395</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho V, McLean A, Terry S. Severe systemic lupus erythematosus induced by antiviral treatment for hepatitis C. J Clin Rheumatol (2008) 14(3):166&#x2013;8. doi: 10.1097/RHU.0b013e3181775e80</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/RHU.0b013e3181775e80</ArticleId><ArticleId IdType="pubmed">18525437</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang N, Leng X, Tian X, Zhao Y, Zeng X. Clinical analysis of 6 patients with drug-induced lupus. Zhonghua Nei Ke Za Zhi (2016) 55(3):211&#x2013;5. doi:&#xa0;10.3760/cma.j.issn.0578-1426.2016.03.011</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/cma.j.issn.0578-1426.2016.03.011</ArticleId><ArticleId IdType="pubmed">26926374</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan Z, Zhou M, Gao T. Clinical characteristics of interferon alpha induced system lupus erythromatosis and literature review. Chin J Clin (Electronic Edition) (2012) 6(04):921&#x2013;3. doi:&#xa0;10.3877/cma.j.issn.1674-0785.2012.04.029</Citation><ArticleIdList><ArticleId IdType="doi">10.3877/cma.j.issn.1674-0785.2012.04.029</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldman KE, Marshall MK, Alessandrini E, Bernstein ML. Complications of alpha-interferon therapy for aggressive central giant cell lesion of the maxilla. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2005) 100(3):285&#x2013;91. doi: 10.1016/j.tripleo.2004.11.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tripleo.2004.11.024</ArticleId><ArticleId IdType="pubmed">16122654</ArticleId></ArticleIdList></Reference><Reference><Citation>Lodato F, Tame M-R, Colecchia A, Racchini C, Azzaroli F, D'Errico A, et al. . Systemic lupus erythematosus following virological response to peginterferon alfa-2b in a transplanted patient with chronic hepatitis C recurrence. World J Gastroenterol (2006) 12(26):4253&#x2013;5. doi: 10.3748/wjg.v12.i26.4253</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v12.i26.4253</ArticleId><ArticleId IdType="pmc">PMC4087386</ArticleId><ArticleId IdType="pubmed">16830387</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbott IJ, Chang CC, Skinner MJ, Street A, Perry G, McLean C, et al. . Development and management of systemic lupus erythematosus in an HIV-infected man with hepatitis C and B co-infection following interferon therapy: a case report. J Med Case Rep (2009) 3:7289. doi: 10.4076/1752-1947-3-7289</Citation><ArticleIdList><ArticleId IdType="doi">10.4076/1752-1947-3-7289</ArticleId><ArticleId IdType="pmc">PMC2726516</ArticleId><ArticleId IdType="pubmed">19830165</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta D, Mohanty S, Thakral D, Bagga A, Wig N, Mitra DK. Unusual association of hemophagocytic lymphohistiocytosis in systemic lupus erythematosus: cases reported at tertiary care center. Am J Case Rep (2016) 17:739&#x2013;44. doi: 10.12659/AJCR.899433</Citation><ArticleIdList><ArticleId IdType="doi">10.12659/AJCR.899433</ArticleId><ArticleId IdType="pmc">PMC5065291</ArticleId><ArticleId IdType="pubmed">27733745</ArticleId></ArticleIdList></Reference><Reference><Citation>Fava A, Petri M. Systemic lupus erythematosus: Diagnosis and clinical management. J Autoimmun (2019) 96:1&#x2013;13. doi: 10.1016/j.jaut.2018.11.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2018.11.001</ArticleId><ArticleId IdType="pmc">PMC6310637</ArticleId><ArticleId IdType="pubmed">30448290</ArticleId></ArticleIdList></Reference><Reference><Citation>Janka GE, Lehmberg K. Hemophagocytic syndromes&#x2013;an update. Blood Rev (2014) 28(4):135&#x2013;42. doi: 10.1016/j.blre.2014.03.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.blre.2014.03.002</ArticleId><ArticleId IdType="pubmed">24792320</ArticleId></ArticleIdList></Reference><Reference><Citation>Jordan MB, Allen CE, Weitzman S, Filipovich AH, McClain KL. How I treat hemophagocytic lymphohistiocytosis. Blood (2011) 118(15):4041&#x2013;52. doi: 10.1182/blood-2011-03-278127</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2011-03-278127</ArticleId><ArticleId IdType="pmc">PMC3204727</ArticleId><ArticleId IdType="pubmed">21828139</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin G, Shenoi S, Hughes GC. Hemophagocytic lymphohistiocytosis: An update on pathogenesis, diagnosis, and therapy. Best Pract Res Clin Rheumatol (2020) 34(4):101515. doi: 10.1016/j.berh.2020.101515</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.berh.2020.101515</ArticleId><ArticleId IdType="pubmed">32387063</ArticleId></ArticleIdList></Reference><Reference><Citation>La Rosee P, Horne A, Hines M, von Bahr Greenwood T, Machowicz R, Berliner N, et al. . Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood (2019) 133(23):2465&#x2013;77. doi: 10.1182/blood.2018894618</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2018894618</ArticleId><ArticleId IdType="pubmed">30992265</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P, Cron RQ, Hartwell J, Manson JJ, Tattersall RS. Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome. Lancet Rheumatol (2020) 2(6):e358&#x2013;67. doi: 10.1016/S2665-9913(20)30096-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(20)30096-5</ArticleId><ArticleId IdType="pmc">PMC7198216</ArticleId><ArticleId IdType="pubmed">32373790</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xf6;nmez HE, Demir S, Bilginer Y, &#xd6;zen S. Anakinra treatment in macrophage activation syndrome: a single center experience and systemic review of literature. Clin Rheumatol (2018) 37(12):3329&#x2013;35. doi: 10.1007/s10067-018-4095-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-018-4095-1</ArticleId><ArticleId IdType="pubmed">29663156</ArticleId></ArticleIdList></Reference><Reference><Citation>De Benedetti F, Grom AA, Brogan PA, Bracaglia C, Pardeo M, Marucci G, et al. . Efficacy and safety of emapalumab in macrophage activation syndrome. Ann Rheum Dis (2023) 82(6):857&#x2013;65. doi: 10.1136/ard-2022-223739</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard-2022-223739</ArticleId><ArticleId IdType="pmc">PMC10314091</ArticleId><ArticleId IdType="pubmed">37001971</ArticleId></ArticleIdList></Reference><Reference><Citation>Chellapandian D, Milojevic D. Case report: Emapalumab for active disease control prior to hematopoietic stem cell transplantation in refractory systemic juvenile idiopathic arthritis complicated by macrophage activation syndrome. Front Pediatr (2023) 11:1123104. doi: 10.3389/fped.2023.1123104</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fped.2023.1123104</ArticleId><ArticleId IdType="pmc">PMC9986425</ArticleId><ArticleId IdType="pubmed">36891226</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>